# A Trial of AK104 Plus Anlotinib in NSCLC

> **NCT04646330** · PHASE1,PHASE2 · COMPLETED · sponsor: **Akeso** · enrollment: 114 (actual)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** AK104+anlotinib
- **DRUG:** AK104+anlotinib
- **DRUG:** AK104+anlotinib

## Key facts

- **NCT ID:** NCT04646330
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-18
- **Primary completion:** 2023-10-26
- **Final completion:** 2025-07-30
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2025-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04646330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04646330, "A Trial of AK104 Plus Anlotinib in NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04646330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*